正在加载公司
Nyxoah SA
NYXH · Nasdaq · ·
US$1.39-14.5%9月29日 收盘
- 1M
- -7.0%
- 6M
- -56.3%
- 1Y
- -72.0%
- 5Y
- -95.1%
NYXH · Nasdaq · ·
US$1.39-14.5%9月29日 收盘
截至 2025年6月30日 的季度，与去年同季度相比。
| 指标 | 截至该日的 3 个月2025年6月30日 | 截至该日的 3 个月2024年6月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$1.5M | US$875.5K | +73.80% |
| 利润 | -US$419.00 | -US$679.03 | +38.29% |
| 每股收益 | -US$0.63 | -US$0.27 | -127.69% |
这些是单季度数字，不是滚动一年——本站其他地方的数字覆盖十二个月，会大得多。季节性业务在两者之间摆动很大：ServiceNow 在十二月季度赚 20 亿美元自由现金流，在六月季度只有 5 亿。
对比对象是去年同一季度，而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据，那是我们没有的授权数据——而搞错它比不提更糟。
暂无 Nyxoah SA 的业绩电话会文字记录。
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete 3 Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study in 2024 and receipt of approval from the FDA in August 2025.
公司自己的描述，取自公告末尾。
引述和公司简介来自 Nyxoah SA 于 2026年8月5日 随业绩提交的 6-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。